Back
Compare AU
Compare EMXC vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares MSCI Emerging Markets Ex China ETF (EMXC) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
EMXC | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 74 |
Median incremental investment | $5,000.00 | $652.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $8,567.26 | $1,364.31 |
Average age group | > 35 | > 35 |
Key Summary
EMXC | CURE | |
|---|---|---|
Strategy | EMXC.AX was created on 2024-06-07 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | ISHARES MSCI EM EX-CHINA UCI USDHD (99.97 %) USD CASH (0.02 %) EUR CASH (0.01 %) | Exact Sciences Corp (3.23 %) Alnylam Pharmaceuticals Inc (3.16 %) Neurocrine Biosciences Inc (2.89 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.25 % | 0.45 % |
Key Summary
EMXC | CURE | |
|---|---|---|
Issuer | iShares | Global X |
Tracking index | MSCI EM (Emerging Markets) ex China | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.25 % | 0.45 % |
Price | $28.51 | $44.01 |
Size | $154.374 million | $29.574 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.19 % | 4.24 % |
Market | ASX | ASX |
First listed date | 12/06/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
EMXC | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 74 |
Median incremental investment | $5,000.00 | $652.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $8,567.26 | $1,364.31 |
Average age group | > 35 | > 35 |
Pros and Cons
EMXC | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
EMXC | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |